BLAINJECTIONINJECTABLE
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUFLYMA is an adalimumab biosimilar (ADALIMUMAB-AATY) approved by the FDA in May 2023, developed by Celltrion. As a TNF-alpha inhibitor monoclonal antibody, it mirrors the mechanism of the reference biologic adalimumab (Humira) for treating inflammatory and autoimmune conditions. The product represents a follow-on biologic alternative in a mature therapeutic class.
Growth
Recent approval positions YUFLYMA in early growth phase with opportunities for commercial build-out, medical affairs expansion, and market penetration strategy development.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Yuflyma® (Adalimumab), Patient Experience After Switching
Started Jun 2022
300 enrolled
Rheumatoid ArthritisAnkylosing SpondylarthritisAxial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis+3 more
Career Relevance
Working on YUFLYMA offers entry into a high-competition biosimilar market requiring strong payer negotiation, formulary management, and rapid market penetration skills. Career growth depends on successfully capturing market share in the crowded adalimumab biosimilar segment and building sustainable differentiation beyond price.
Brand Manager
Worked on YUFLYMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.